La vendita allo scoperto per Herbalife dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Herbalife. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Herbalife (NYSE:HLF) Azioni, Report sulle vendite allo scoperto

Herbalife

Herbalife Nutrition

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management; targeted nutrition; Energy, Sports, and Fitness; Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Mexico, South and Central America, EMEA, Asia-Pacific, and China.

Scopri le tre azioni su cui gli insider stanno investendo massicciamente e le motivazioni dietro questi acquisti strategici.

Le 3 azioni su cui gli insider scommettono forte: ecco perché

Herbalife Ltd

HONG LEONG BANK BHD by Hong Leong Bank BHD

HONG LEONG FINCL GRP ORD by Hong Leong Financial Group BHD

Hong Leong Financial Group Bhd

HALFORDS GROUP PLC ORD by Halfords Group Plc

Halfords Group PLC

HALFORDS GROUP UNSP/ADR by Halfords Group Plc

HelloFresh SE

HILTON FOOD GROUP ADR by HILTON FOOD GROUP PLC

Hilton Food Group PLC

HOME LOAN FINCL CORP by Home Loan Financial Corp.

Home Loan Financial Corp

DA Davidson analyst Linda Bolton Weiser maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and lowers the price target from $13 to $7.5.

News

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Herbalife, Lowers Price Target to $7.5

WIIM

Herbalife shares are trading higher after the company reported better-than-expected Q3 financial results.

B. Riley Securities analyst Jeff Van Sinderen maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Buy and lowers the price target from $17 to $12.

B. Riley Securities Maintains Buy on Herbalife, Lowers Price Target to $12

Guidance

Herbalife Expects Q4 Net Sales To Be (3.0)% To +1.0% YoY; Narrows FY24 Range To (2.0)% - (1.0)% YoY (Prior View (3.5)% To +1.5% )

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.35 by 62.86 percent. This is a 12.31 percent decrease over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $1.24 billion which met the analyst consensus estimate. This is a 3.20 percent decrease over sales of $1.28 billion the same period last year.

Earnings

Earnings Beats

Herbalife Q3 2024 Adj EPS $0.57 Beats $0.35 Estimate, Sales $1.24B Inline

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is a &#8220;very inexpensive stock, and I am inclined down here at $17 to be as positive as you are.&#8221;
Hewlett Packard Enterprise CEO Antonio Neri recently defended the company's decision to continue its $4 billion lawsuit against the estate of Mike Lynch, following the tech magnate's recent death.
Cramer also likes Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The Redmond, Washington-based tech giant announced a new share repurchase program worth up to $60 billion. 
Microsoft also declared a quarterly dividend of 83 cents per share, marking a 10% increase from the previous quarter.
NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) is a &#8220;red hot stock, but the cohort's red hot. I don't think it's done, I think it can go higher.&#8221;
On Sept. 3, Wells Fargo analyst Neil Kalton maintained NextEra Energy with an Overweight rating and raised the price target from $95 to $102.
Cramer said Alight, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) has not been able to make money so far. &#8220;I want to see that company actually make money before I opine on it,&#8221; he added.
On Aug. 26, Alight named Dave Guilmette as Chief Executive Officer and reiterated its 2024 second half business outlook.
Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) has no growth and he doesn't want to touch it. &#8220;Too controversial, too crazy. Let's move on,&#8221; he added.
On July 31, Herbalife reported worse-than-expected second-quarter revenue results and lowered its FY24 revenue growth below estimates.
Price Action:
<ul>
<li>NextEra Energy shares slipped 0.01% to settle at $84.64 on Monday.</li>
<li>Alight shares rose 0.7% to close at $7.28 during Monday's session.</li>
<li>Herbalife shares fell 4.9% to settle at $7.06.</li>
<li>Microsoft shares rose 0.2% to close at $431.34 on Monday.</li>
<li>Hewlett Packard shares gained 0.5% to settle at $17.23 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40877520/if-you-want-steel-you-do-nucor-says-cramer-when-asked-about-gerdau">&#8216;If You Want Steel, You Do Nucor,&#8217; Says Cramer When Asked About Gerdau</a></li>
</ul>
Image: Shutterstock

ALIT

MSFT

Cramer: Hewlett Packard Is A 'Very Inexpensive' Stock, Likes This Big Tech Stock

In a recent episode of &#8220;Mad Money,&#8221; host Jim Cramer has deemed the stock of Herbalife Nutrition Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) as excessively controversial and unpredictable, in light of a 50% plunge in its value over the past year.
What Happened: During the lightning round of his show on Friday, Cramer addressed a viewer&#8217;s inquiry about Herbalife. As per <a href="https://www.cnbc.com/2024/09/16/cramers-lightning-round-herbalife-is-too-controversial-too-crazy.html">CNBC</a> on Tuesday, Cramer&#8217;s candid evaluation was, &#8220;No growth. Don't want to touch it. Too controversial, too crazy. Let's move on.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40869320/micha-l-van-de-poppe-predicts-massive-bitcoin-surge-says-price-may-soar-by-890?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michaël Van De Poppe Predicts Massive Bitcoin Surge, Says Price May Soar By 890%</a>
This statement follows a substantial decrease in the value of Herbalife&#8217;s stock. The stock has shed over half its value in the past year, leading to heightened scrutiny and investor apprehension.
Why It Matters: The sharp decline in the value of Herbalife has not been without reason. The company&#8217;s most significant challenge was its multi-level marketer (MLM) business model, as per BofA Securities. In 2023, analyst Anna Lizzu initiated coverage of Herbalife Nutrition with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30707892/why-this-herbalife-nutrition-analyst-cannot-digest-the-business-model">an Underperform rating</a> and a price target of $14, reflecting the skepticism surrounding the company&#8217;s business model.
Price Action: Herbalife closed 4.85% lower on Monday at 7.06, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40866592/swifties-rally-for-kamala-harris-taylor-swift-superfan-organizes-online-push-for-democratic-ticket?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Swifties Rally For Kamala Harris: Taylor Swift Superfan Organizes Online Push For Democratic Ticket</a>\</li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Analyst Color

Equities

Markets

General

Jim Cramer Thinks This Stock, Which Has Lost Over 50% Value In One Year, Is 'Too Controversial, Too Crazy'

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Herbalife </h3>
<ul>
<li>The Trade: Herbalife Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) Juan Miguel Mendoza <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $7.11. To acquire these shares, it cost around $71,100.</li>
<li>What's Happening: On July 31, Herbalife reported worse-than-expected second-quarter revenue results.</li>
<li>What Herbalife Does: Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model.</li>
</ul>
<h3 class="wp-block-heading">PBF Energy</h3>
<ul>
<li>The Trade: PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) 10% owner Control Empresarial de Capitales S.A. de C.V. <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,257,800 shares at</a> an average price of $32.45. To acquire these shares, it cost around $40.8 million.</li>
<li>What's Happening: PBF Energy will release its earnings results for the third quarter 2024 on Thursday, Oct. 31.</li>
<li>What PBF Energy Does: PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States.</li>
</ul>
<h3 class="wp-block-heading">Limbach Holdings</h3>
<ul>
<li>The Trade: Limbach Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) Director David Richard Gaboury <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,200 shares</a> at an average price of $62.20. The insider spent around $74,640 to buy those shares.</li>
<li>What's Happening: On Sept. 3, Limbach Holdings, said it has acquired Kent Island Mechanical, LLC.</li>
<li>What Limbach Holdings Does: Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40773243/top-2-health-care-stocks-that-may-collapse-this-quarter">Top 2 Health Care Stocks That May Collapse This Quarter</a></li>
</ul>

More Than $40M Bet On This Energy Stock? Check Out These 3 Stocks Executives Are Aggressively Buying

Although U.S. stocks closed slightly higher on Tuesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Weyerhaeuser</h3>
<ul>
<li>The Trade: Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) Director Albert Monaco <a href="https://www.benzinga.com/quote/WY/analyst-ratings">acquired a total of 31,500 shares at </a> an average price of $31.38. To acquire these shares, it cost around $988,376.</li>
<li>What's Happening: On July 25, Weyerhaeuser reported downbeat second-quarter sales.</li>
<li>What Weyerhaeuser Does: Weyerhaeuser ranks among the world&#8217;s largest forest product companies.</li>
</ul>
<h3 class="wp-block-heading">El Pollo Loco</h3>
<ul>
<li>The Trade: El Pollo Loco Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) 10% owner Biglari Insurance Group Inc. acquired a total of 344,247 shares at an average price of $13.20. To acquire these shares, it cost around $4.5 million.</li>
<li>What's Happening: On Aug. 1, El Pollo Loco posted upbeat quarterly earnings.</li>
<li>What El Pollo Loco Does: El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States.</li>
</ul>
<h3 class="wp-block-heading">Herbalife</h3>
<ul>
<li>The Trade: Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) Director Juan Miguel Mendoza <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $8.72. To acquire these shares, it cost around $87,200.</li>
<li>What's Happening: On July 31, Herbalife reported worse-than-expected second-quarter revenue results.</li>
<li>What Herbalife Does: Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40576188/microsoft-synaptics-and-2-other-stocks-executives-are-selling">Microsoft, Synaptics And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Long Ideas

Insider Trades

Pre-Market Outlook

Trading Ideas

LOCO

$4.5M Bet On This Consumer Cyclical Stock? Check Out These 3 Stocks Executives Are Buying

Herbalife shares are trading lower after the company reported worse-than-expected Q2 revenue results. Additionally, the company lowered its FY24 revenue growth below estimates.

B. Riley Securities analyst Jeff Van Sinderen maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Buy and raises the price target from $16 to $17.

B. Riley Securities Maintains Buy on Herbalife, Raises Price Target to $17

DA Davidson analyst Linda Bolton Weiser maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and raises the price target from $9.5 to $13.

DA Davidson Maintains Neutral on Herbalife, Raises Price Target to $13

Full-year 2024&nbsp;guidance&nbsp;revised: net sales reduced, adjusted EBITDA&nbsp;raised, capital expenditures reaffirmed.

Herbalife Expects Q3 Net Sales To Decline (4.5)% To 0% Y/Y; Revises FY24 Sales Growth Outlook To (3.5)% To +1.5% (Prior View 0% To +5%)

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.39 by 38.46 percent. This is a 27.03 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $1.281 billion which missed the analyst consensus estimate of $1.329 billion by 3.60 percent. This is a 2.51 percent decrease over sales of $1.314 billion the same period last year.

Earnings Misses

Herbalife Q2 2024 Adj. EPS $0.54 Beats $0.39 Estimate, Sales $1.281B Miss $1.329B Estimate

CVS Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvs#NYSE">CVS</a>), the pharmacy retail and PBM powerhouse, has witnessed a substantial 24% decline over the past three months. In fact, during the last trading session, the stock closed at $56.62, which marked a more than 47% plunge from its 52-week high of $83.25 and was quite close to its 52-week low of $52.77.
Not only this, the stock is currently trading below its 50-day and 200-day moving averages, indicating the possibility of a further bearish shift in the stock&#39;s price.
<h3>CVS Below 50 &amp; 200 Day SMA</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/10/70629.jpg?v=964484543" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
As the stock struggles to keep pace, it is now a big question for investors whether to get rid of CVS Health or grab a few more shares because the stock is hovering around its rock bottom. While the stock has been grappling with the industry-wide phenomenon of pharmacy reimbursement pressure, a turnaround might be in the cards, given its strategic initiatives that can change investors&#39; perspectives in favor of CVS Health. Let us delve deeper.
<h3>What Pulled CVS Down?</h3>
Pharmacy Reimbursement Crisis: The entire retail pharmacy industry is currently grappling with continued pressure from non-reimbursable pharmacy expenses, which are significantly pulling down mass demand for prescription as well as over-the-counter drugs and vaccinations. Going by a National Association of Chain Drugs report, payors are substantially shrinking reimbursement, many times below the cost of buying and dispensing prescription drugs. This is putting substantial and unsustainable financial pressure on the companies to the extent that many of the industry players over the past year were seen either shutting down their entire business, reducing the number of stores or going private. CVS Health, like its industry peers, is severely affected by this ongoing crisis. In fact, despite the company reporting revenue expansion, the shrinking margins and earnings are pretty alarming.
Labor Shortage Plagues the System: Despite the end of the healthcare emergency, the lingering effects forced frontline pharmacy retail workers like doctors and medical staff to leave the field. According to the article &quot;A Public Health Crisis: Staffing Shortages in Health Care,&quot; published in Favorite Healthcare Staffing, the WHO predicts a shortfall of 15 million healthcare workers worldwide in 2030. This is naturally creating huge operational hazards for companies like CVS Health, resulting in productivity loss. Going by a 2024 Boston Globe report, CVS has, in fact, acknowledged an &quot;unprecedented&quot; labor shortage among pharmacists and other staff, leading customers to complain about longer lines, unanswered phones and unclean stores.
<h3>Visible Silver Lining for CVS</h3>
<h3>2025 Roadmap Looks Impressive</h3>
CVS Health is committed to improving its Medicare Advantage margins in 2025. Given its predicted baseline performance, 2025 will be the first stage in a three to four-year journey to re-establish the company&#39;s target margins of 4 to 5%. Improved Star Ratings in 2025 might generate a $700 million tailwind, depending on membership retention levels. The remainder of the company&#39;s margin gain in 2025 will be driven by pricing initiatives in an environment where it is experiencing headwinds from an insufficient rate notice and prescription medication coverage changes that significantly raise plan liability.
CVS Health is accelerating long-term enterprise productivity measures to streamline and enhance its processes. The company&#39;s target remains to achieve low double-digit adjusted EPS growth in 2025.
<h3>Shares Outperform Industry</h3>
Over the past month, shares of CVS Health have lost 6.1%. However, the stock has outperformed the industry&#39;s 9.6% decline. While one of the company&#39;s peers, Herbalife Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>), registered a 2% decline, outperforming CVS, the company&#39;s prime competitor and another colossal pharmacy retail player, Walgreens Boots (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>), suffered a sharper decline of 29.4% during this period due to disappointing quarterly results and further guidance cut due to unfavorable industry forecasts.
<h3>One-Month Price Comparison</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/70630.jpg?v=1381530106" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Upbeat Estimates</h3>
With CVS&#39; second-quarter 2024 results approaching, we expect the company to fare better than WBA. Not to forget, the company has the power to minimize its pharmacy reimbursement-related issues by adjusting its in-house PBM business strategies.
The Zacks Consensus Estimate points to revenue improvements of 3.1% and 5.5% for 2024 and 2025, respectively. However, reimbursement issues are likely to continue through the rest of 2024, creating significant bottom-line pressure for CVS Health. The Zacks Consensus Estimate indicates an earnings decline of 19.7% in 2024. However, there is some hope for investors that 2025 might get brighter, with the estimates showing a 10.6% improvement in earnings from the year-ago period.
The stock currently has a Growth Score&nbsp;of A.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e3/70631.jpg?v=1680805760" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Waiting for a Better Entry Point Seems Prudent</h3>
As we have already discussed, the stock is currently positioned below its moving averages, which indicates potential negative movement. Further, the current earnings estimates show no visible sign of improvement until 2025.
In terms of valuation too, CVS Health&#39;s forward 12-month price-to-earnings (P/E) is 7.65X, a premium to the market&#39;s average of 7.09X. The company is also trading at a significant premium to other industry players like Walgreens Boots (4.9X) and Herbalife (6.8X). This suggests that investors may be paying a higher price relative to the company&#39;s expected earnings growth.
<h3>Premium Valuation</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fb/70632.jpg?v=1847936069" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
Accordingly, despite the recent dip in share prices, this might not be the ideal time to invest in CVS Health. However, those who already own this Zacks Rank #3 (Hold) stock may stay invested as the company&#39;s financial stability and 2025 roadmap offer potential pathways to recovery.
<a href="https://www.zacks.com/stock/news/2297788/cvs-health-cvs-falls-24-in-3-months-should-you-buy-the-dip?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2297788">To read this article on Zacks.com click here.</a>

Health Care

Small Cap

CVS Health Falls 24% in 3 Months: Should You Buy the Dip?

Taking a multivitamin <a href="https://www.benzinga.com/markets/emerging-markets/23/12/36205088/inside-the-multibillion-dollar-supplement-industry-trends-and-insights">once a day</a> has long been considered a path to better health, but a new study refutes that widely held belief.
A study published in JAMA Network Open on Wednesday revealed that after tracking nearly 400,000 healthy adults for over 20 years, researchers found no link between regular multivitamin use and a lower risk of death, <a href="https://www.nih.gov/news-events/news-releases/healthy-adults-taking-multivitamins-daily-not-associated-lower-risk-death#:~:text=The%20analysis%20showed%20that%20people,heart%20disease%2C%20or%20cerebrovascular%20diseases">according </a>to the National Institutes of Health.
The study was led by researchers at the National Institutes of Health's National Cancer Institute.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/23/07/33309720/healthcare-advocates-united-a-push-for-congress-to-recognize-cbd-as-dietary-supplements">Healthcare Advocates United: A Push For Congress To Recognize CBD As Dietary Supplements</a>
&#8220;The analysis showed that people who took daily multivitamins did not have a lower risk of death from any cause than people who took no multivitamins,&#8221; Erikka Loftfield, Ph.D., M.P.H., a researcher with the division of cancer epidemiology and genetics at the National Cancer Institute, wrote in the study.
&#8220;There were also no differences in mortality from cancer, heart disease, or cerebrovascular diseases. The results were adjusted for factors such as race and ethnicity, education, and diet quality.&#8221;
Loftfield also emphasized the importance of assessing the risk of death associated with multivitamin use in different populations, such as those with documented nutritional deficiencies. She highlighted the need to explore the potential impact of regular multivitamin use on aging-related health conditions.
Price Action: Despite the study&#8217;s findings on multivitamin use, related health and wellness companies saw varied market reactions. By Thursday&#8217;s afternoon trading, BellRing Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) gained 1.08% to $57.89, Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) slipped 1.03% to $10.52, and USANA Health Sciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) was up 1% to $45.44.
Invesco S&amp;P SmallCap Consumer Staples ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCC#NASDAQ">PSCC</a>) slipped 0.09% by early afternoon, while VegTech Plant-based Innovation &amp; Climate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EATV#NYSE">EATV</a>) remained unchanged and Invesco Food &amp; Beverage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBJ#NYSE">PBJ</a>) declined 0.68%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31554925/gianni-di-poce-rings-the-bell-on-bellring-brands-calls-for-42-returns">Gianni Di Poce Rings The Bell On BellRing Brands, Calls For 42% Returns</a></li>
</ul>
Photo: Shutterstock

ETFs

BRBR

Advisors Series Trust VegTech Plant-based Innovation & Climate ETF

EATV

PSCC

USNA

Multivitamins Show No Link To 'Lower Risk of Death,' Study Finds

Last month, Nestlé SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGF#OTC">NSRGF</a>)&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>)&nbsp;unveiled&nbsp;Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38949073/weight-loss-drugs-like-wegvoy-and-zepbound-users-nestl-launches-5-pizza-for-you" rel="noreferrer noopener">focused on weight management</a>.&nbsp;
The European food giant said the company will not mention the weight loss drugs on the packaging.
Tom Moe, President of Meals at Nestle USA, stated that the company&#8217;s Vital Pursuit line would be marketed primarily through social media to avoid regulatory issues.
&#8220;We won&#8217;t directly make the connection (to the drugs) on the food package,&#8221; Moe emphasized in a Reuters report.
This decision highlights the regulatory uncertainties that global food companies face when targeting the growing market of people using appetite-suppressing medications, such as Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Wegvoy and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.
The medications, known as GLP-1 agonists, have impacted snack-makers and fast-food chains as consumers reduce their food intake.
Reuters report adds that Nestle&#8217;s Vital Pursuit products will compete with brands that make specific claims for people who are on these medications.
For example, Biocare, a drink priced at $4.50 per serving, claims to alleviate side effects like nausea for users of semaglutide, the active ingredient in Wegovy and Ozempic.
Referencing weight-loss drugs on Vital Pursuit packaging could lead to regulatory scrutiny. &#8220;We&#8217;re not a medication, we&#8217;re a food product,&#8221; Moe noted. Mentioning medications could imply that the food treats or prevents disease, a claim only FDA-approved products can make.
The report further quoted Lauren Handel, an attorney specializing in food regulations, who advised that the safest approach is to avoid mentioning any drugs. &#8220;It&#8217;s a tricky area where you&#8217;d want to be careful about what you say,&#8221; she said, noting that labeling products as &#8220;suitable for people on a diet&#8221; may comply with regulations.
Nestle has not disclosed whether it will refer to the drugs in advertisements.
In contrast, Herbalife Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) has taken a direct approach, promoting its GLP-1 Companion Pack on Facebook to support the nutritional needs of people using GLP-1 weight-loss drugs.
Frank Lamberti, Herbalife&#8217;s Chief Commercial Officer, said the company avoids brand names like Ozempic to avoid alienating users of other drugs such as Eli Lilly&#8217;s Mounjaro and Zepbound.
Other companies, including Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) and yogurt-maker Danone (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DANOY#OTC">DANOY</a>), are positioning their products as suitable for weight-loss medications due to their low sugar or high protein content. Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), maker of Healthy Choice meals, will also avoid drug names on packaging.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Biotech

Large Cap

Media

DANOY

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

Nestle Carefully Targets Weight-Loss Drug Users with New Food Line

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut the price target for Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) from $5 to $2.5. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Big Lots shares dipped 18.2% to close at $2.88 on Thursday. <a href="https://www.benzinga.com/quote/BIG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer raised the price target for Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) from $118 to $130. Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating. Addus HomeCare shares rose 1.2% to close at $116.07 on Thursday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $450 to $500. Oppenheimer analyst Timothy Horan maintained an Outperform rating. Microsoft shares gained 0.1% to close at $424.52 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $5.9 to $6. B of A Securities analyst Ming Hsun Lee maintained a Neutral rating. NIO shares fell 6.8% to close at $4.91 on Thursday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) price target from $262 to $259. Stifel analyst Jeffrey Stantial maintained a Buy rating. Vail Resorts shares gained 0.6% to close at $193.95 on Thursday. <a href="https://www.benzinga.com/quote/MTN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho boosted Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) price target from $10 to $11. Mizuho analyst John Baumgartner maintained a Neutral rating. Herbalife shares rose 1.7% to close at $11.43 on Thursday. <a href="https://www.benzinga.com/quote/HLF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised the price target for 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) from $105 to $120. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. 3M shares fell 0.9% to close at $98.22 on Thursday. <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) price target from $65 to $55. Baird analyst William Power maintained a Neutral rating. DocuSign shares rose 2% to close at $54.60 on Thursday. <a href="https://www.benzinga.com/quote/DOCU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham slashed Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) price target from $65 to $60. Needham analyst Ryan Koontz maintained a Buy rating. Ciena shares rose 0.7% to close at $48.56 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) price target from $66 to $55. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Braze shares gained 2% to close at $36.78 on Thursday. <a href="https://www.benzinga.com/quote/BRZE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39224737/wall-streets-most-accurate-analysts-weigh-in-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Risk Off Stocks Delivering High-Dividend Yields</a>

ADUS

BRZE

CIEN

DOCU

Microsoft To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Mizuho analyst John Baumgartner maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and raises the price target from $10 to $11.

Mizuho Maintains Neutral on Herbalife, Raises Price Target to $11

The earnings results for Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) for Q1 were made public on Wednesday, May 1, 2024 at 04:35 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Herbalife beat estimated earnings by 44.0%, reporting an EPS of $0.49 versus an estimate of $0.34.
Revenue was up $12.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company missed on EPS by $0.11 in the last quarter, resulting in a 32.0% drop share price change the following day.
Here's a look at Herbalife's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.34</td>
<td>0.39</td>
<td>0.73</td>
<td>0.69</td>
<td>0.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.28</td>
<td>0.65</td>
<td>0.74</td>
<td>0.54</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.26B</td>
<td>1.19B</td>
<td>1.25B</td>
<td>1.28B</td>
<td>1.21B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.26B</td>
<td>1.22B</td>
<td>1.28B</td>
<td>1.31B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>

<h3>Latest Earnings Reports from Competitors</h3>
With Herbalife's earnings data in hand, it's essential to compare its metrics to those of similar companies, including Olaplex Hldgs, Beauty Health, and Lifevantage.
<ul>
<li>Olaplex Hldgs's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.03 compared to the estimated EPS of $0.03, resulting in a 0.0% increase.</li>
<li>Beauty Health announced strong earnings on May 09, 2024, surpassing market expectations. Despite an estimated EPS of $-0.14, Beauty Health's actual EPS was $-0.1, reflecting a 28.57% increase.</li>
<li>Lifevantage announced strong earnings on May 02, 2024, surpassing market expectations. Despite an estimated EPS of $0.16, Lifevantage's actual EPS was $0.21, reflecting a 31.25% increase.</li>
</ul>
<h3>Unpacking Competitors' Quarterly Earnings and Stock Performance</h3>
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>May 1, 2024</td>
<td style="text-align: right;">0.34</td>
<td style="text-align: right;">0.49</td>
<td>44.12%</td>
<td>$8.68</td>
<td>$9.56</td>
<td>10.14%</td>
</tr>
<tr>
<td>Olaplex Hldgs</td>
<td>May 02, 2024</td>
<td style="text-align: right;">0.03</td>
<td style="text-align: right;">0.03</td>
<td>0.0%</td>
<td>$1.64</td>
<td>$1.68</td>
<td>2.44%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>May 09, 2024</td>
<td style="text-align: right;">-0.14</td>
<td style="text-align: right;">-0.10</td>
<td>28.57%</td>
<td>$3.59</td>
<td>$3.2</td>
<td>-10.86%</td>
</tr>
<tr>
<td>Lifevantage</td>
<td>May 02, 2024</td>
<td style="text-align: right;">0.16</td>
<td style="text-align: right;">0.21</td>
<td>31.25%</td>
<td>$6.11</td>
<td>$6.06</td>
<td>-0.82%</td>
</tr>
</tbody>
</table>

<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
The following table compares estimated and announced revenue figures for Herbalife's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>1.26B</td>
<td>1.26B</td>
<td>0.32%</td>
</tr>
<tr>
<td>Olaplex Hldgs</td>
<td>95.25M</td>
<td>98.91M</td>
<td>3.84%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>80.53M</td>
<td>81.40M</td>
<td>1.08%</td>
</tr>
<tr>
<td>Lifevantage</td>
<td>52.18M</td>
<td>48.24M</td>
<td>-7.54%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Herbalife <a href="https://www.benzinga.com/quote/HLF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Herbalife: Q1 Earnings Insights

Here are the major earnings after the close today

Pre-earnings options volume in Herbalife (HLF) is 4.6x normal with puts leading calls 25:1. Implied volatility suggests the market is anticipating ...

Herbalife options imply 13.3% move in share price post-earnings

Sees Q4 sales down 3% to up 1% year-over-year relative to last year's $1.215B, consensus $1.20B. Published first on TheFly – the ultimate source fo...

Herbalife sees Q4 adjusted EBITDA $105M-$135M

Reports Q3 revenue $1.20B, consensus $1.24B. The company said, "Our financial foundation is strong. Third quarter net sales were in line with our e...

Herbalife reports Q3 EPS 46c, consensus 35c

Herbalife Non-GAAP EPS of $0.57 beats by $0.27, revenue of $1.24B misses by $10M

Herbalife ( ($HLF) ) has provided an update. Herbalife reported third-quarter 2024 financial results with net sales of $1.2 billion, slightly down ...

Herbalife Reports Strong Q3 2024 Despite Currency Impact

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Root&nbsp;(ROOT)&nbsp;up 70.4...

Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats

Herbalife Ltd. (HLF) Q3 2024 Earnings Call Transcript

Herbalife Ltd. 2024 Q3 - Results - Earnings Call Presentation

Herbalife (HLF) is up 17.1%, or $1.17 to $7.97. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

Herbalife rises 17.1%

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

ATEC

AXAHY

BECN

BKNG

CFLT

COIN

COMP

CORT

CVNA

DASH

DAWN

EBAY

ETSY

HOOD

HTGC

HUBG

IMAX

INVH

IRTC

JAKK

KLAC

LMND

LPLA

MATX

MPWR

OLED

PAYC

PPSI

RELY

RIOT

ROKU

ROOT

SBUX

SIMO

SNBR

SPOK

SPXC

SSNLF

STAA

STEM

TDOC

TENB

TWLO

Press Releases

Herbalife and Herbalife Family Foundation Commit $1 Million to World Food Program USA Benefitting Women-led Agribusiness in Colombia

Herbalife Expands Board of Directors with Appointment of Perkins Miller

Herbalife to Announce Second Quarter 2024 Results on July 31

Herbalife Reports Second Quarter 2024 Results, Adjusted EBITDA1 Exceeds Guidance; Raised Full-Year Adjusted EBITDA1 Guidance

Herbalife Scientists to Showcase Advancements in Ingredient Safety and Nutritional Quality at 2024 AOAC INTERNATIONAL Annual Meeting

Herbalife to Participate in Barclays Global Consumer Staples Conference on September 3

Herbalife Champions Community Wellness at 31st Annual Ketchum-Downtown YMCA Stair Climb and Urban Hike

Herbalife to Announce Third Quarter 2024 Results on October 30

Herbalife Sets GUINNESS WORLD RECORDS™ Title with 2024 Worldwide Workout

Herbalife Reports Third Quarter 2024 Results, Net Sales In Line with Expectations, Adjusted EBITDA1 Exceeds Guidance; Raised Full-Year Adjusted EBITDA1 Guidance

Comments

Herbalife

Vendite allo scoperto

Herbalife (NYSE:HLF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO